Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Le Rêve 3.0: A Double-Blind, Placebo-Controlled, Randomized, Crossover Investigational Study to Determine if Defined CBD, a Capsule With a Custom Formulation of Cannabidiol (CBD) and Terpenes, Influences Sleep Physiology

NCT05233761 is registered in ClinicalTrials.gov with Defined Research as lead sponsor.

NCT NCT05233761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05233761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Le Rêve 3.0: A Double-Blind, Placebo-Controlled, Randomized, Crossover Investigational Study to Determine if Defined CBD, a Capsule With a Custom Formulation of Cannabidiol (CBD) and Terpenes, Influences Sleep Physiology
Lead sponsor
Defined Research
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2022
Completion date
July 2, 2022
Enrollment
125 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia